Voices
Joshua Brody: Impressive Study – Adding Bispecific Ab Immunotherapy to Chemotherapy
Joshua Brody/LinkedIn

Joshua Brody: Impressive Study – Adding Bispecific Ab Immunotherapy to Chemotherapy

Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn:

“Impressive study – adding bispecific Ab immunotherapy to chemo yields amazing response rate of ~80% in patients with relapsed aggressive.”

Joshua Brody: Impressive Study - Adding Bispecific Ab Immunotherapy to Chemotherapy

Title: Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

Authors: Pau Abrisqueta, Yasmin H. Karimi, Daniel Morillo, Raúl Cordoba, Tycel Phillips, Sven de Vos, Marcel Nijland, Fritz Offner, Per-Ola Andersson, Joshua Brody, Chan Y. Cheah, Pilar Gomez Prieto, Mats Hellström, Judit Meszaros Jørgensen, David Lewis, Kim M. Linton, Gerardo Musuraca, Liwei Wang, Jennifer Marek, Kojo Osei-Bonsu, Malene Risum, Lorenzo Falchi

Read the full article on Hematologica.

Joshua Brody: Impressive Study - Adding Bispecific Ab Immunotherapy to Chemotherapy

Other articles featuring Joshua Brody on OncoDaily.

cancer Chan Y. Cheah Daniel Morillo David Lewis Fritz Offner Gerardo Musuraca Jennifer Marek Joshua Brody Judit Meszaros Jørgensen Kim M Linton Kojo Osei-Bonsu Liwei Wang Lorenzo Falchi Malene Risum Marcel Nijland Mats Hellström OncoDaily Oncology Pau Abrisqueta Per-Ola Andersson Pilar Gómez-Prieto Raul Cordoba Sven de Vos Tycel Phillips Yasmin H. Karimi